Scarica l'app Stockscreener
95.41
0.72%
-0.69
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$96.10
Aprire:
$95.76
Volume 24 ore:
2.16M
Relative Volume:
1.01
Capitalizzazione di mercato:
$18.73B
Reddito:
$4.58B
Utile/perdita netta:
$870.87M
Rapporto P/E:
21.69
EPS:
4.3988
Flusso di cassa netto:
$945.58M
1 W Prestazione:
-6.94%
1M Prestazione:
-11.87%
6M Prestazione:
+37.84%
1 anno Prestazione:
+34.70%
Intervallo 1D:
$93.54
$96.00
Intervallo di 1 settimana:
$93.54
$100.43
Portata 52W:
$53.56
$109.28
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Confronta INCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
95.41 | 18.87B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-08 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-11-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Iniziato | Barclays | Overweight |
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Lures New Top Lawyer With Hefty Equity Package Tied to Performance - MyChesCo
Bellevue Group AG Has $106.94 Million Holdings in Incyte Corporation $INCY - MarketBeat
Incyte Corporation (INCY) Announces Retirement of Board Member H - GuruFocus
Incyte director Hervé Hoppenot retires from board effective immediately - Investing.com
Hervé Hoppenot resigns from Incyte’s board of directors - Investing.com
Incyte Announces Change to its Board of Directors - Business Wire
WINTON GROUP Ltd Makes New Investment in Incyte Corporation $INCY - MarketBeat
Ieq Capital LLC Has $27.52 Million Position in Incyte Corporation $INCY - MarketBeat
Incyte’s Blood Cancer Drug Shows Promise, But Hurdles Remain - Finimize
Incyte Corporation $INCY Shares Acquired by Investment Management Corp of Ontario - MarketBeat
Incyte stock rating reiterated by RBC, firm notes ’989 program viability - Investing.com
Jump Financial LLC Purchases 70,768 Shares of Incyte Corporation $INCY - MarketBeat
California Public Employees Retirement System Sells 122,593 Shares of Incyte Corporation $INCY - MarketBeat
Amundi Purchases 101,220 Shares of Incyte Corporation $INCY - MarketBeat
Incyte releases data that shows promise in treating rare blood disease - Delaware Business Now
Sun Pharma Claims New Pill Distinct From Incyte's Hit Drug - Law360
Incyte (NASDAQ:INCY) Upgraded at Mizuho - MarketBeat
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia - BioSpace
Incyte stock holds Market Perform rating at Citizens on CALR therapy lead - Investing.com
Is Incyte Still Attractive After Its Strong 2025 Rally and DCF Valuation Gap? - Yahoo Finance
Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower? - Yahoo Finance
Incyte (INCY) Reports Promising Phase 1 Results for INCA033989 i - GuruFocus
Incyte’s experimental drug shows strong response in blood disorder By Investing.com - Investing.com Canada
Incyte’s experimental drug shows strong response in blood disorder - Investing.com
Incyte presents data showing 90% response rate for blood cancer drug - StreetInsider
Institution Moves: Why Incyte Corporation ICY stock stays undervaluedWatch List & Short-Term Trading Alerts - BỘ NỘI VỤ
Incyte (NASDAQ:INCY) Trading Down 6.6%Should You Sell? - MarketBeat
Incyte (INCY) Maintained as Equal-Weight by Morgan Stanley with Raised Price Target | INCY Stock News - GuruFocus
INCY: Wells Fargo Raises Price Target to $116 | INCY Stock News - GuruFocus
Incyte gains FDA Breakthrough designation for its candidate against essential thrombocythemia - marketscreener.com
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status - Yahoo Finance
Incyte (INCY) Stock Receives Upgraded Rating and Price Target fr - GuruFocus
What's Going On With Incyte Stock Monday?Incyte (NASDAQ:INCY) - Benzinga
Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer - Sahm
Leerink Partners Adjusts Incyte Price Target to $128 From $103, Maintains Outperform Rating - marketscreener.com
Incyte stock price target raised to $128 by Leerink on mCALR data - Investing.com
Incyte Corporation $INCY Shares Purchased by American Century Companies Inc. - MarketBeat
Incyte Says Rare Blood Cancer Therapy Receives FDA Breakthrough Designation - marketscreener.com
Incyte Names Veteran Biopharma Attorney as New General Counsel - MyChesCo
Wells Fargo Adjusts Price Target on Incyte to $116 From $97, Maintains Overweight Rating - marketscreener.com
Mizuho upgrades Incyte stock rating to Outperform on promising ASH data - Investing.com
Incyte stock price target raised by BofA to $118 on promising blood disorder data - Investing.com
Mizuho Upgrades Incyte to Outperform From Neutral, Adjusts Price Target to $121 From $90 - marketscreener.com
First Trust Advisors LP Sells 12,101 Shares of Incyte Corporation $INCY - MarketBeat
Transcript : Incyte CorporationSpecial Call - marketscreener.com
Incyte (INCY) Secures FDA Breakthrough Therapy Designation for I - GuruFocus
Incyte (INCY) Reveals Promising Phase 1 Results for INCA033989 i - GuruFocus
Incyte (INCY) Receives FDA Breakthrough Therapy Designation for INCA033989 - GuruFocus
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025 - Yahoo Finance
18,946 Shares in Incyte Corporation $INCY Bought by 1832 Asset Management L.P. - MarketBeat
Incyte: Buy At This Inflection Point (NASDAQ:INCY) - Seeking Alpha
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.07%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):